Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study.
Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study.
复制标题
DOI：
10.1002/hed.26820
复制
发表时间：
2021-11
期刊：
影响因子：
--
通讯作者：
Phan J
中科院分区：
文献类型：
--
作者：
Diao K;Nguyen TP;Moreno AC;Reddy JP;Garden AS;Wang CH;Tung S;Wang C;Wang XA;Rosenthal DI;Fuller CD;Gunn GB;Frank SJ;Morrison WH;Shah SJ;Lee A;Spiotto MT;Su SY;Ferrarotto R;Phan J
复发的头颈癌预后较差。立体定向全身放射治疗(SBRT)可以通过提供消融性辐射剂量来改善预后。我们回顾了2013-2020年间在我们机构接受明确意向SBRT再次照射的患者。分析失败模式、总生存期(OS)和毒性反应。对137例患者进行了评估。中位OS为44.3个月。SBRT中位剂量为45Gy，中位靶区体积为16.9cc。1年内局部控制率为78%，区域控制率为66%，远控率为83%。在非转移性患者中，系统治疗改善了区域(p=0.004)和远程控制(p=0.04)。3级以上毒性更多见于黏膜部位(p=0.001)和同时进行全身治疗(p=0.02)。在大量接受SBRT再次照射的复发性小体积头颈部癌患者中，观察到中位OS为44.3个月。系统治疗改善了区域和远程控制。毒副作用可通过解剖部位和全身治疗进行调节。
Recurrent head and neck cancer has poor prognosis. Stereotactic body radiotherapy (SBRT) may improve outcomes by delivering ablative radiation doses. We reviewed patients who received definitive-intent SBRT reirradiation at our institution from 2013–2020. Patterns of failure, overall survival (OS), and toxicities were analyzed. 137 patients were evaluated. The median OS was 44.3 months. The median SBRT dose was 45 Gy and median target volume 16.9 cc. The 1-year local, regional, and distant control was 78%, 66%, and 83%, respectively. Systemic therapy improved regional (p=0.004) and distant control (p=0.04) in non-metastatic patients. Grade 3+ toxicities were more common at mucosal sites (p=0.001) and with concurrent systemic therapy (p=0.02). In a large cohort of SBRT reirradiation for recurrent, small volume head and neck cancers, a median OS of 44.3 months was observed. Systemic therapy improved regional and distant control. Toxicities were modulated by anatomic site and systemic therapy.
登录
查看更多内容
影响因子：
2.9
作者：
Mukoyama N;Suzuki H;Hanai N;Sone M;Hasegawa Y
通讯作者：
Hasegawa Y
影响因子：
5.7
作者：
Lartigau, Eric F.;Tresch, Emmanuelle;Kramar, Andrew
通讯作者：
Kramar, Andrew
DOI：
10.1097/coc.0000000000000118
发表时间：
2017-04
期刊：
American journal of clinical oncology
影响因子：
--
作者：
Gurka MK;Kim C;He AR;Charabaty A;Haddad N;Turocy J;Johnson L;Jackson P;Weiner LM;Marshall JL;Collins SP;Pishvaian MJ;Unger K
通讯作者：
Unger K
DOI：
10.1097/coc.0b013e3181dbb73e
发表时间：
2011-04-01
影响因子：
2.6
作者：
Heron, Dwight E.;Rwigema, Jean-Claude M.;Ferris, Robert L.
通讯作者：
Ferris, Robert L.
影响因子：
3.9
作者：
Diao, Kevin;Bian, Shelly X.;Chang, Eric L.
通讯作者：
Chang, Eric L.